Cargando…

A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA’s Sentinel Initiative

Detalles Bibliográficos
Autor principal:	Brown, Joshua D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390989/ https://www.ncbi.nlm.nih.gov/pubmed/32715968 http://dx.doi.org/10.18553/jmcp.2020.26.8.1050

Ejemplares similares

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

FDA’s tracking and analysis of surveillance sampling isolates for outbreak detection
por: Blessington, Tyann, et al.
Publicado: (2017)

FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
por: Yu, Lawrence X., et al.
Publicado: (2019)

The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023)

The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future
por: Xu, Joshua, et al.
Publicado: (2016)

Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022)

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
por: Mooghali, Maryam, et al.
Publicado: (2023)

COVID-19 emergency responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, Lieutenant Commander Andrea, et al.
Publicado: (2020)

LAWS, REGULATIONS, AND POLICY: Genetically Engineered Salmon on the FDA’s Table
por: Taylor, David A.
Publicado: (2010)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
por: Lee, Sarah, et al.
Publicado: (2023)

WITHDRAWN: COVID-19 Emergency Responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, LCDR Andrea, et al.
Publicado: (2020)

OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
por: Kass-Hout, Taha A, et al.
Publicado: (2016)

The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic
por: Diak, Ida-Lina, et al.
Publicado: (2022)

FDA’s Strategies to Close the Health Equity Gap among Diverse Populations
por: Spinner, Jovonni, et al.
Publicado: (2021)

Awareness of and receptivity to FDA’s point-of-sale tobacco public education campaign
por: Dutra, Lauren M., et al.
Publicado: (2023)

US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
por: Echols, Roger M, et al.
Publicado: (2021)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
por: Osman, Amira, et al.
Publicado: (2018)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
por: Vatsan, Ramjay S, et al.
Publicado: (2013)

A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
por: Niazi, Sarfaraz K.
Publicado: (2023)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

FDA’s Nozzle Numerical Simulation Challenge: Non-Newtonian Fluid Effects and Blood Damage
por: Trias, Miquel, et al.
Publicado: (2014)

Can the COVID-19 interstate travel restrictions help lift the FDA’s blood ban?
por: Dorfman, Doron
Publicado: (2020)

The FDA’s Diverse and Dynamic Activities in the Social and Behavioral Sciences: Advancing and Supporting Health Equity
por: Lee, Christine, et al.
Publicado: (2021)

338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
por: Linfield, Rebecca, et al.
Publicado: (2023)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
por: Degnan, Fred H.
Publicado: (2012)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
por: Kramer, Judith M., et al.
Publicado: (2014)

Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA’s criteria
por: Vandenberg, Laura N., et al.
Publicado: (2023)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
por: Chiu, Kimberly, et al.
Publicado: (2023)

A Primer to the Structure, Content and Linkage of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) Files
por: Ensign, Lisa Garnsey, et al.
Publicado: (2017)

The FDA’s standard-making process for medical digital health technologies: co-producing technological and organizational innovation
por: Lievevrouw, Elisa, et al.
Publicado: (2021)

Narrative Review: The FDA’s Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events
por: Li, WeiQi, et al.
Publicado: (2023)

Enhancing FDA’s Reach to Minorities and Under-Represented Groups through Training: Developing Culturally Competent Health Education Materials
por: Spinner, Jovonni R., et al.
Publicado: (2021)

Could the vaginal wall sling still have a role after FDA’s warning? the functional outcomes at 20 years
por: Illiano, Ester, et al.
Publicado: (2022)

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2021)

A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework
por: Mutanga, Jane Namangolwa, et al.
Publicado: (2023)

More Than 7 Years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications
por: Regier, Emily E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e6inpir7qda8d6ccia19ikjfje